In 1998, the global cardiovascular market expanded by 7.2%, growing in value
from $60bn in 1997 to almost $65bn in 1998. Market expansion is being driven
by expanding prevalent populations in the major markets.
However, as many of the older cardiovascular products approach patent expiry,
companies are having to look to alternative revenue sources in order to maintain
sales growth. Many companies are looking to sustain cardiovascular sales through
additional indications and novel drug delivery technologies for their products,
but this will not be sufficient to halt a sales decline in particular segments
of the cardiovascular market over the next five years.
The Cardiovascular Outlook, 1998-2010 draws upon extensive primary research
from industry opinion leaders to provide an overview of the cardiovascular market,
its present state and future developments. The report analyses the epidemiological
trends, examines the impact of new therapies drawing to the end of their development,
identifies areas of unmet need, and gives insight into the dynamics of the market.
Epidemiology :
The epidemiological trends for the cardiovascular markets are examined, and
predictions given from detailed in-house forecasting models, including breakdowns
by country for incidence, mortality and detection.
Analysis of the market :
The main products in each market are identified and are benchmarked according
to their 1998 sales and competitive positioning. Sales are forecast to 2010
for each product considered.
Unmet need :
The areas of unmet need in the cardiovascular area, both therapeutic unmet need
and needs of the drug purchasers and providers, are discussed.
New therapeutics :
Proprietary in-house databases are used to identify the main players in R&D
in each market and to analyse their pipeline. The drugs in development and expected
launch dates are used to highlight changes in competitive intensity in each
market.
